Epilepsy: complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalization; generalized tonic-clonic seizures; mixed forms of seizures. Finlepsin can be used as a monotherapy or as part of a combination therapy. Acute manic States; supportive therapy for bipolar affective disorders in order to prevent exacerbations or reduce the clinical manifestations of exacerbation. Alcohol withdrawal syndrome. Idiopathic trigeminal neuralgia and trigeminal neuralgia in multiple sclerosis (typical and atypical). Idiopathic neuralgia of the pharyngeal nerve.
active substance: carbamazepine;
1 tablet contains carbamazepine 200 mg;
excipients: microcrystalline cellulose, gelatin, croscarmellose sodium, magnesium stearate.
Finlepsin Dosage form
Basic physical and chemical properties: white round tablets with a double-sided chamfer and a deep line on one side, convex on the other side, with a smooth surface, solid edges and the same appearance.
Finlepsin Pharmacotherapeutic group
Antiepileptic drugs. Carboxamide derivatives. Carbamazepine. ATX code N03A F01.
As an anticonvulsant agent, carabamazepine is effective in partial seizures (simple and complex) with and without secondary generalization; generalized tonic-clonic convulsive seizures, as well as with a combination of these types of seizures.
The mechanism of action of carbamazepine is only partially determined. Carbamazepine stabilizes the membranes of very excited nerve fibers, inhibits the occurrence of repeated neuronal discharges and reduces synaptic conduction of excitatory impulses. It was found that the main mechanism of action of the drug is to prevent the re-formation of sodium-dependent action potentials in depolarized neurons by blocking sodium channels. The anticonvulsant effect of the drug is mainly due to a decrease in the release of glutamate and stabilization of neuronal membranes, while the anti-manic effect may be due to inhibition of the metabolism of dopamine and norepinephrine.
Suction. After oral administration, carbamazepine is absorbed almost completely, although somewhat slowly. After a single dose of a regular tablet, the maximum plasma concentration (Cmax) is reached after 12 hours. There are no clinically significant differences in the degree of absorption of the active substance after the use of different dosage forms of the drug for oral administration. After a single oral administration of a tablet containing 400 mg of carbamazepine, the average Cmax of the unchanged active substance reaches about 4.5 μg / ml.
The bioavailability of various oral dosage forms of carbamazepine has been shown to be in the range of 85-100%.
Food intake does not significantly affect the rate and extent of carbamazepine absorption.
Equilibrium concentrations of the drug in blood plasma are achieved within 1-2 weeks, which depends on the individual characteristics of metabolism (autoinduction of liver enzyme systems with carbamazepine, heteroinduction with other drugs that are used simultaneously), as well as on the patient’s condition, dose of the drug and duration of treatment. There are significant interindividual differences in the values of equilibrium concentrations in the therapeutic range: in most patients, these values range from 4 to 12 μg / ml (17-50 μmol / L). Concentrations of carbamazepine-10,11-epoxide (pharmacologically active metabolite) reach almost 30% compared to the concentrations of carbamazepine.
complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalization;
generalized tonic-clonic seizures;
mixed forms of convulsive seizures.
Finlepsin® can be used as monotherapy and as part of combination therapy.